A Regulatory Perspective on Biosimilar Medicines
By definition, biosimilar medicinal products are biological medicinal products that are similar to other biological medicinal products that are already on the market-the reference medicinal products. Access to biosimilar medicines is a current reality. However, to achieve this goal, it is extremely...
Saved in:
Main Authors: | Marta Agostinho Cordeiro (Author), Carla Vitorino (Author), Carlos Sinogas (Author), João J. Sousa (Author) |
---|---|
Format: | Book |
Published: |
MDPI AG,
2024-02-01T00:00:00Z.
|
Subjects: | |
Online Access: | Connect to this object online. |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Biosimilars: Current regulatory perspective and challenges
by: Diwakar Jha, et al.
Published: (2013) -
On the Regulatory Approval Pathway of Biosimilar Products
by: Jun Wang, et al.
Published: (2012) -
Biosimilars: State of Clinical and Regulatory Science
by: Agnes Victoria Klein, et al.
Published: (2018) -
Current regulatory and market environment for biosimilars in Serbia
by: Pejović Gordana, et al.
Published: (2014) -
Biosimilars in Oncology: Latest Trends and Regulatory Status
by: Deeksha Joshi, et al.
Published: (2022)